Cancer Related Molecular Pathways / DNA Repair Mechanisms · Journal article

Emerging roles of ATR beyond DNA damage repair: orchestrating transcriptional reprogramming during epithelial-to-mesenchymal transition

Journal of Clinical Investigation · August 17, 2026

Hypothesis-Generating Why this matters to you Expert discussion

Raises a question worth testing. It does not answer one.

AI Summary

This is a journal commentary that synthesizes two concurrent primary studies proposing that ATR kinase, beyond its known role in DNA damage response, orchestrates transcriptional reprogramming during epithelial-to-mesenchymal transition (EMT) by preventing R-loop accumulation and responding to extracellular matrix stiffness. The commentary frames these as mechanistic discoveries with potential therapeutic implications for targeting metastasis and therapy resistance, but does not itself present clinical trial data or clinical endpoints.

What was studied

Journal article. Cancer cells undergoing epithelial-to-mesenchymal transition; no human clinical population specified..

Key findings

Patel et al. demonstrated that ATR prevented R-loop accumulation at EMT-related gene loci, facilitating transcriptional reprogramming necessary for EMT, tumor growth, and metastasis. Tu et al. uncovered a role for ATR in ECM stiffness-induced EMT associated with an immunosuppressive tumor microenvironment.

Safety

No discussion of potential safety or tolerability concerns with ATR targeting.

Who this may help

These findings suggest ATR inhibition may have therapeutic potential in preventing metastasis and overcoming therapy resistance, but clinical translation and efficacy in human patients remain to be established.

Plain-language summary

This is a journal commentary synthesizing two concurrent primary studies; it raises mechanistic questions about ATR's role in EMT and metastasis but does not itself present original empirical data or a definitive clinical trial result.

Clinical bottom line

Caveats

This is a commentary, not a primary research report; no original data, effect sizes, confidence intervals, or p-values are provided.
The clinical applicability of mechanistic findings in cancer cell models to human patients is not addressed.
No discussion of potential safety or tolerability concerns with ATR targeting.
The relative importance of ATR's role in EMT versus its established function in DNA damage response is not quantified.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Commentary synthesizing findings; no primary design reported.

Directness

limited

Discusses mechanistic roles in EMT and metastasis; clinical translation not stated.

Consistency

moderate

Two concurrent studies cited; both implicate ATR in EMT via different mechanisms.

Risk of bias

insufficient

Commentary does not report bias assessment or study quality metrics.

Sample adequacy

insufficient

No sample size or power analysis provided in commentary.

What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

The ability of cancer cells to transition between epithelial and mesenchymal states, a process known as epithelial-to-mesenchymal transition (EMT), is a key driver of cancer metastasis and therapy resistance. While ataxia telangiectasia and Rad3-related (ATR) kinase was originally characterized as a responder to DNA damage and replication stress, recent discoveries implicate a critical role for ATR in EMT and metastasis. Two pivotal studies published in this issue of JCI provide key insights into how ATR intersects with EMT transcriptional reprogramming. Patel et al. demonstrated that ATR prevented R-loop accumulation at EMT-related gene loci, thereby facilitating the transcriptional reprogramming necessary for EMT as well as tumor growth and metastasis. Tu et al. further uncovered a role for ATR in ECM stiffness-induced EMT, which was associated with an immunosuppressive tumor microenvironment. Together, these studies highlight important therapeutic implications for ATR targeting in the context of metastasis and therapy resistance.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.